PREDICTING PROGNOSIS IN CLASSIC HODGKIN LYMPHOMA
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 9, 2014
app pub date -
Dec 7, 2012
filing date -
Dec 9, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Predictor genes and methods for determining prognosis in classic Hodgkin's lymphoma (cHL) are described herein. Expression levels of predictor genes ALDH1A1, APOL6, B2M, CD300A, CD68, CXCL11, GLUL, HLA-A, HLA-C, IFNG, IL15RA, IRF1, LMO2, LYZ, PRF1, RAPGEF2, RNF144B, STAT1, TNFSF10, WDR83, CCL17, COL6A1, and PDGFRA are used to derive a score within a prognostic model. Measurement of expression levels may involve counting RNA molecules using digital profiling, such as the NanoString™ platform. The score is compared to a threshold indicative of outcome. Associated kits, commercial packages, panels of biomarkers, and uses are also provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully